# Noriva — Market Analysis
## GLP-1 Supplement Opportunity Assessment
*Prepared February 2026*

---

## 1. GLP-1 Medication Market Overview

### 1.1 The GLP-1 Revolution

GLP-1 receptor agonists (GLP-1 RAs) represent the largest pharmaceutical disruption in a generation. Originally developed for Type 2 diabetes management, drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have transformed the weight loss landscape and created an entirely new category of patients with unique nutritional needs.

**Key Medications in Market:**

| Drug | Manufacturer | Indication | Approval Year | Est. US Patients |
|------|-------------|-----------|---------------|-----------------|
| Ozempic (semaglutide) | Novo Nordisk | T2D | 2017 | ~10M+ |
| Wegovy (semaglutide) | Novo Nordisk | Obesity | 2021 | ~3M+ |
| Mounjaro (tirzepatide) | Eli Lilly | T2D | 2022 | ~5M+ |
| Zepbound (tirzepatide) | Eli Lilly | Obesity | 2023 | ~2M+ |
| Saxenda (liraglutide) | Novo Nordisk | Obesity | 2014 | ~1M |
| Rybelsus (oral semaglutide) | Novo Nordisk | T2D | 2019 | ~2M |

### 1.2 Market Size & Growth

- **GLP-1 RA Global Market (2025):** ~$50B in annual sales (Novo Nordisk + Eli Lilly combined)
- **Novo Nordisk Obesity Revenue (2024):** Wegovy alone generated ~$8.3B globally
- **Eli Lilly GLP-1 Revenue (2024):** Mounjaro + Zepbound combined ~$15.5B
- **Projected GLP-1 Market (2030):** $100–150B globally (Goldman Sachs, Morgan Stanley estimates)
- **CAGR:** 25–35% annual growth through 2030

### 1.3 Adoption Curves

According to the **KFF Health Tracking Poll (May 2024):**
- **12% of US adults** (roughly 31M people) have ever taken a GLP-1 drug
- **6% of US adults** (~15.6M) are *currently* taking a GLP-1 drug
- **82% of adults** have heard of GLP-1 drugs (up from 70% in July 2023)
- **32%** have heard "a lot" about these drugs (up from 19% in July 2023)

**Demographic Breakdown:**
- Ages 50-64: 19% have ever taken GLP-1s (highest adoption)
- Black adults: 18% ever use (vs. 10% White adults)
- Hispanic adults: 13% ever use
- Among those told they're overweight/obese: 22% have taken GLP-1s
- Among diabetics: 43% have taken GLP-1s

**Growth Trajectory:**
- 2021: ~2M US users
- 2022: ~5M US users
- 2023: ~10M US users
- 2024: ~20M US users
- 2025: ~30M US users (estimated)
- 2030: ~50-70M US users (projected, with oral formulations and expanded indications)

### 1.4 Semaglutide & Tirzepatide Adoption Curves

**Semaglutide (Novo Nordisk):**
- First-mover advantage with Ozempic (2017) and Wegovy (2021)
- Supply constraints limited growth in 2022-2023; now largely resolved
- Oral semaglutide (Rybelsus) expanding access for needle-averse patients
- New high-dose oral semaglutide (25mg/50mg) in late-stage trials — could be a game-changer for accessibility

**Tirzepatide (Eli Lilly):**
- Dual GIP/GLP-1 mechanism showing superior weight loss (~22.5% in SURMOUNT-1)
- Mounjaro approved for T2D (2022), Zepbound for obesity (2023)
- Rapidly gaining market share, especially for weight loss indication
- Eli Lilly investing $9B+ in manufacturing capacity

**Pipeline Drugs (2025-2030):**
- Amgen: MariTide (monthly injection, potential 2026 approval)
- Viking Therapeutics: VK2735 (oral and injectable)
- Pfizer: Danuglipron (oral GLP-1)
- Roche: CT-996 (oral, daily)
- Structure Therapeutics: GSBR-1290 (oral)

*Every new drug entering the market expands the total addressable market for GLP-1 support supplements.*

---

## 2. Target Customer Personas

### Persona 1: "Steady Sarah" — The Health-Conscious Weight Manager

**Demographics:**
- Female, 38-52
- Suburban, household income $85K-$150K
- College-educated, career professional or working mom
- BMI 30-38

**GLP-1 Journey:**
- On Wegovy or Zepbound for 3-9 months
- Prescribed through primary care or telehealth (Hims, Found, Ro)
- Experiencing steady weight loss (15-30 lbs so far)
- Insurance covers part; paying $200-400/month out of pocket

**Pain Points:**
- Noticing hair thinning at month 3-4 — alarmed and searching for solutions
- Energy levels are low despite weight loss
- Worried about losing muscle, not just fat
- Existing multivitamin feels inadequate for her new physiology
- Overwhelmed by contradictory supplement advice on TikTok and Reddit

**Buying Behavior:**
- Researches extensively before purchasing (reads reviews, checks ingredients)
- Subscribes to 2-3 wellness newsletters
- Active in GLP-1 Facebook groups and Reddit r/Ozempic
- Willing to pay premium for science-backed, targeted products
- Values subscription convenience — doesn't want to think about reordering

**Where to Reach Her:**
- Instagram, TikTok (health/wellness content)
- GLP-1 Reddit communities (r/Ozempic, r/Mounjaro, r/Zepbound)
- Google search: "best supplements for Ozempic" "hair loss on Wegovy"
- Facebook groups: "Ozempic & Wegovy Weight Loss Support"
- Podcast ads on health/wellness shows

---

### Persona 2: "Fit Mike" — The Body Composition Optimizer

**Demographics:**
- Male, 32-48
- Urban/suburban, household income $100K-$200K
- Fitness-oriented, has a gym membership, tracks macros
- BMI 28-35

**GLP-1 Journey:**
- On Mounjaro or Zepbound for 2-6 months
- Prescribed through telehealth or endocrinologist
- Concerned about body composition, not just scale weight
- Already doing resistance training but seeing lean mass decline on DEXA scans

**Pain Points:**
- DEXA scan showed 35-40% of weight lost was lean mass — he's frustrated
- Wants to maximize fat loss while preserving muscle
- Protein intake is down because appetite is suppressed
- GI issues (nausea, constipation) disrupt his training schedule
- Current protein powder/BCAA stack doesn't address GLP-1-specific needs

**Buying Behavior:**
- Data-driven — wants to see clinical studies and dosages
- Already spends $100-200/month on supplements
- Follows fitness influencers and biohacking content
- Values transparent labeling and third-party testing
- Prefers monthly subscription with ability to customize

**Where to Reach Him:**
- YouTube (fitness/biohacking channels)
- Reddit (r/fitness, r/supplements, r/Mounjaro)
- Instagram fitness influencers
- Podcasts: Huberman Lab, Peter Attia, Mind Pump
- Google: "muscle loss on tirzepatide" "best supplements to prevent muscle loss GLP-1"

---

### Persona 3: "Diabetic Diana" — The Chronic Condition Manager

**Demographics:**
- Female, 48-65
- Suburban/rural, household income $55K-$95K
- Managing Type 2 diabetes + obesity
- BMI 33-42

**GLP-1 Journey:**
- On Ozempic for 12+ months (originally for diabetes, now also losing weight)
- Prescribed by endocrinologist or primary care
- Insurance covers medication for diabetes indication
- Experiencing significant weight loss (30-60 lbs) but also nutritional depletion

**Pain Points:**
- Lab work shows declining B12, vitamin D, and iron levels
- Doctor recommended "a good multivitamin" but didn't specify which
- Experiencing fatigue, brain fog, and mood changes
- Digestive issues have been persistent since starting medication
- Concerned about bone density with rapid weight loss and aging

**Buying Behavior:**
- Trusts doctor recommendations and clinical evidence
- Price-sensitive but will pay for products her doctor endorses
- Shops primarily on Amazon or direct-to-consumer websites
- Values simplicity — wants one package that covers her needs
- Less tech-savvy; prefers email communication over social media

**Where to Reach Her:**
- Google search: "vitamin deficiency on Ozempic" "supplements for diabetics on semaglutide"
- Amazon search: "GLP-1 support supplement"
- Doctor/nutritionist referrals (B2B healthcare provider channel)
- Email marketing (health newsletters, diabetes education)
- Facebook groups for diabetes management

---

### Persona 4: "Trendy Taylor" — The Aesthetic-Driven Early Adopter

**Demographics:**
- Female, 25-35
- Urban, household income $65K-$120K
- Image-conscious, active on social media
- BMI 26-32 (slightly overweight, not obese)

**GLP-1 Journey:**
- On compounded semaglutide or brand-name Wegovy for 1-4 months
- Got prescription through telehealth (Hims, Ro, Found)
- Primary motivation is aesthetic — wants to look thinner, not managing disease
- Paying out-of-pocket ($200-500/month) since insurance won't cover for BMI <30

**Pain Points:**
- Nausea is ruining her social life (can't eat at restaurants, avoids alcohol)
- Already noticing skin changes — dullness, dryness
- Terrified of "Ozempic face" (facial volume loss from rapid weight loss)
- Wants to maintain her hair, skin, and nails during weight loss
- Sees other influencers posting about GLP-1 supplements — wants in

**Buying Behavior:**
- Heavily influenced by social media (TikTok, Instagram)
- Buys based on aesthetic packaging and brand identity
- Values clean, trendy branding (thinks Ritual, Moon Juice, Sakara)
- Happy to share products on her own social media
- Impulse purchaser — will buy after seeing one compelling video

**Where to Reach Her:**
- TikTok (GLP-1 content, beauty/wellness creators)
- Instagram (aesthetic wellness brands, before/after content)
- Influencer partnerships
- Google: "Ozempic face prevention" "supplements for GLP-1 skin" "Ozempic nausea relief natural"
- Pinterest (wellness boards)

---

## 3. Customer Pain Points & Unmet Needs

### 3.1 Clinical Evidence for GLP-1 Nutritional Challenges

A landmark 2026 narrative review published in *Clinical Obesity* (Urbina et al., PMID: 41549912) analyzing 480,825 adults on GLP-1 RA therapy found:

**Nutrient Deficiencies:**
- **Vitamin D deficiency:** 7.5% at 6 months → 13.6% at 12 months
- **Iron depletion:** GLP-1 users showed 26-30% lower ferritin levels vs. SGLT2 inhibitor users
- **Calcium & Iron intake:** >60% of users consumed below estimated requirements
- **Vitamin D intake:** Averaged only 20% of recommended levels
- **B12 deficiency:** Increased over time due to altered gastric absorption
- **Thiamine depletion:** Progressive decline, especially concerning for neurological health

**Muscle & Body Composition:**
- Per Neeland et al. (2024, PMID: 38937282): lean mass reductions range from 15-60% of total weight lost
- STEP 1 trial (Wilding et al., NEJM 2021): ~40% of weight lost on semaglutide was lean body mass
- SURMOUNT-1 trial (Jastreboff et al., NEJM 2022): Similar lean mass loss proportions with tirzepatide
- Case report (Donigan et al., 2025, PMID: 40956288): Severe polyradiculopathy from micronutrient deficiencies in a semaglutide patient post-bariatric surgery

**Hair Loss:**
- Systematic review (Alsuwailem et al., 2025, PMID: 41111833) confirmed GLP-1 RA-associated hair loss (telogen effluvium)
- Pharmacovigilance data (Kim et al., 2025, PMID: 40176478): GLP-1 RAs were the most reported drug class for hair loss adverse events
- Typically begins 3-6 months after starting therapy
- Driven by rapid weight loss, caloric restriction, and nutrient depletion (iron, zinc, biotin, protein)

**Gastrointestinal Issues:**
- 40-50% of patients experience nausea (most common side effect)
- 20-30% experience constipation
- 15-25% experience diarrhea
- GI issues are the #1 reason for therapy discontinuation

### 3.2 Unmet Needs Matrix

| Pain Point | Current Solutions | Gap | Noriva Solution |
|-----------|------------------|-----|----------------|
| Nutrient depletion | Generic multivitamins | Not formulated for reduced caloric intake; missing GLP-1-specific needs | Essential Multi with enhanced B12, D3, iron, zinc, magnesium |
| Muscle loss | Protein powder, BCAAs | Not targeting GLP-1-specific mechanisms; lacking HMB, creatine, vitamin D | Muscle Guard with HMB, creatine, vitamin D3, leucine |
| GI distress | OTC antacids, ginger tea | No targeted GLP-1 digestive formula; probiotics not specific to gastric slowing | Gut Ease with ginger, probiotics, digestive enzymes, peppermint |
| Hair/skin changes | Biotin gummies, collagen | Generic beauty supplements; not addressing root cause nutrient deficiencies | Hair + Glow with biotin, zinc, iron, keratin, collagen, saw palmetto |
| All of the above | Multiple products from different brands | No single brand addressing the full GLP-1 spectrum; no bundle | The Bundle — complete system, 35% savings |

---

## 4. Market Size Calculations

### 4.1 Total Addressable Market (TAM)

**US GLP-1 Patient Population:**
- Current users (2025): ~30M Americans have ever used; ~15M currently using
- Projected users (2028): ~40-50M ever used; ~25-30M active users
- Projected users (2030): ~50-70M ever used; ~35-45M active users

**Global Supplement Spending (GLP-1 Adjacent):**
- US dietary supplements market (2025): ~$60B
- Weight management supplements segment: ~$8B
- Vitamins & minerals segment: ~$18B

**TAM Calculation:**
- US adults who have ever taken GLP-1s: 30M (2025)
- Average monthly supplement spend per health-conscious consumer: $45-85
- Conservative capture rate of supplement buyers among GLP-1 users: 40%
- **TAM = 30M × 40% × $65/mo × 12 = $93.6B annually**

*More conservatively, if only current active users (15M) and average $50/month:*
- **Conservative TAM = 15M × 40% × $50 × 12 = $36B**

### 4.2 Serviceable Addressable Market (SAM)

Narrowing to DTC supplement buyers who:
- Are actively on GLP-1 medications (15M)
- Purchase supplements online (65% of supplement buyers)
- Are in income brackets that support premium pricing ($75K+ HHI = ~55%)
- Are aware of GLP-1-specific nutritional needs (~30% and growing)

**SAM = 15M × 65% × 55% × 30% × $55/mo × 12 = $10.7B**

### 4.3 Serviceable Obtainable Market (SOM) — Year 1-3

**Year 1 (2026-2027):**
- Target: 2,000-5,000 active subscribers
- Average revenue per subscriber: $75/month (mix of individual + bundle)
- **SOM Year 1: $1.8M - $4.5M ARR**

**Year 2 (2027-2028):**
- Target: 10,000-25,000 active subscribers
- **SOM Year 2: $9M - $22.5M ARR**

**Year 3 (2028-2029):**
- Target: 30,000-75,000 active subscribers
- **SOM Year 3: $27M - $67.5M ARR**

---

## 5. Growth Drivers & Tailwinds

### 5.1 Macro Tailwinds

1. **Expanding GLP-1 Indications**
   - Heart disease prevention (Wegovy CVOT approved)
   - MASH/NASH liver disease (semaglutide in trials)
   - Alzheimer's disease (early-stage trials)
   - Kidney disease, sleep apnea, addiction
   - Each new indication expands the patient population

2. **Oral GLP-1 Formulations**
   - Oral semaglutide (higher doses) in Phase 3
   - Eli Lilly oral tirzepatide (orforglipron) in trials
   - Oral drugs remove needle barrier → dramatically expand addressable market
   - Could add 20-30M additional users by 2030

3. **Insurance Coverage Expansion**
   - Medicare coverage for weight loss (proposed, bipartisan support — 60% of Americans favor)
   - More commercial insurers adding obesity coverage
   - Employer-sponsored weight management programs growing rapidly

4. **Generic/Biosimilar Entry**
   - Compounded semaglutide already widely available
   - Ozempic patent expires 2031-2032
   - Lower prices = more users = larger supplement market

5. **Growing Awareness of Nutritional Side Effects**
   - PubMed publications on GLP-1 nutrient deficiency: 1 in 2023, 1 in 2024, 3 in 2025, growing rapidly
   - Mainstream media coverage increasing
   - Healthcare providers increasingly recommending supplementation
   - Social media driving awareness (TikTok #OzempicSideEffects has 500M+ views)

### 5.2 Category-Specific Tailwinds

1. **GLP-1 "Ecosystem" Spending**
   - Patients spending $1,000-1,500/month on medication are highly willing to spend $50-130/month on supplements
   - The "sunk cost" effect: having invested heavily in GLP-1 therapy, patients want to maximize outcomes

2. **DTC Supplement Boom**
   - Subscription supplement market growing 15-20% annually
   - Consumers increasingly preferring specialized, condition-specific supplements over generic
   - AG1 proved that premium-priced ($79-99/month) single-brand supplement subscriptions scale massively

3. **Personalization Trend**
   - Consumers want supplements designed for their specific situation
   - "Supplements for GLP-1 users" is a clear, defensible positioning
   - Analogous to prenatal vitamins (specific life stage = specific supplement) — proven category

4. **Content Marketing Opportunity**
   - Massive demand for GLP-1 education content (low supply of trustworthy sources)
   - SEO opportunity is enormous (high search volume, low competition for quality content)
   - Community building around shared experience (GLP-1 journey)

### 5.3 Potential Headwinds

1. **Regulatory Risk**
   - FDA could scrutinize "GLP-1 support" claims
   - Must be careful with structure/function claims vs. disease claims
   - Mitigation: FDA-compliant labeling, legal review of all marketing

2. **Competition Intensifying**
   - More brands entering the GLP-1 supplement space in 2025-2026
   - AG1 already positioning for GLP-1 users (noted on their homepage)
   - Mitigation: First-mover advantage in pure-play GLP-1 supplements, 4-product system creates switching costs

3. **GLP-1 Safety Concerns**
   - Negative media coverage could slow adoption
   - Side effect concerns (pancreatitis, thyroid cancer warnings)
   - Mitigation: Noriva benefits regardless of medication trajectory (nutritional support is always needed)

4. **Economic Sensitivity**
   - Supplements are discretionary spending
   - Recession could reduce willingness to pay premium prices
   - Mitigation: Bundle pricing provides value; subscription creates habit/stickiness

---

## 6. Regulatory Landscape for Supplements

### 6.1 FDA Framework

Dietary supplements are regulated under the **Dietary Supplement Health and Education Act (DSHEA) of 1994**:

- **Registration:** Must register manufacturing facility with FDA
- **GMP Compliance:** Must follow Current Good Manufacturing Practices (cGMP) per 21 CFR Part 111
- **New Dietary Ingredients (NDI):** If using ingredients not marketed before 1994, must file NDI notification
- **Labeling:** Must include Supplement Facts panel, ingredient list, manufacturer info
- **Claims:** 
  - ✅ Structure/function claims allowed (e.g., "supports digestive health")
  - ❌ Disease claims prohibited (e.g., "prevents nutrient deficiency from Ozempic")
  - Must include disclaimer: "These statements have not been evaluated by the FDA..."
- **Adverse Event Reporting:** Must report serious adverse events to FDA within 15 days

### 6.2 Noriva Compliance Strategy

- **Cannot claim** to treat, prevent, or cure side effects of GLP-1 medications
- **Can position** as nutritional support for people with reduced caloric intake
- **Can reference** clinical studies showing nutrient deficiencies in GLP-1 users (educational, not promotional)
- **Must avoid** implying medical advice or treatment
- Recommended approach: "Designed for people on a weight management journey" + educational content about GLP-1 nutritional needs

### 6.3 Certifications Needed

| Certification | Purpose | Timeline | Cost |
|--------------|---------|----------|------|
| cGMP (FDA 21 CFR 111) | Required for all supplement manufacturing | Pre-launch | Included in contract manufacturer |
| NSF Certified for Sport | Athlete trust, quality signal | 3-6 months | $5,000-15,000/SKU |
| USP Verified | Gold standard third-party testing | 6-12 months | $10,000-25,000/SKU |
| Non-GMO Project | Consumer preference | 3-4 months | $3,000-5,000/SKU |
| Informed Sport | Drug-free testing | 2-4 months | $3,000-8,000/SKU |

**Priority:** Launch with cGMP + third-party COA testing. Add NSF/USP within Year 1 as revenue supports it.

---

## 7. Distribution Channel Analysis

### 7.1 Channel Strategy (Phased)

**Phase 1: DTC Website (Launch)**
- Primary channel: noriva.com
- Subscription-first model (subscribe & save pricing)
- One-time purchase available at higher price
- Shopify Plus + Recharge for subscription management
- **Target:** 100% of revenue in first 6 months

**Phase 2: Amazon (Month 4-6)**
- Amazon presence for discovery and credibility
- Higher pricing on Amazon vs. DTC (incentivize direct)
- Amazon Subscribe & Save integration
- Sponsored Products + Sponsored Brands advertising
- **Target:** 20-30% of revenue by Month 12

**Phase 3: Telehealth Partnerships (Month 6-12)**
- Partner with GLP-1 telehealth providers (Found, Ro, Hims/Hers, Alpha Medical)
- Co-branded recommendations in post-prescription communications
- Revenue share or wholesale model
- **Target:** 10-20% of revenue by Month 18

**Phase 4: Healthcare Provider Channel (Month 12-18)**
- Physician dispensing program (sell through doctor's offices)
- Nutritionist/dietitian recommendation program
- Pharmacy partnerships (independent compounding pharmacies)
- **Target:** 5-15% of revenue by Year 2

**Phase 5: Retail (Year 2+)**
- Specialty retail: Whole Foods, Sprouts, Vitamin Shoppe
- Requires proven demand data and significant inventory investment
- Higher margin but more complex operations
- **Target:** Evaluate based on brand awareness and demand signals

### 7.2 Channel Economics

| Channel | Gross Margin | CAC | LTV | Payback Period |
|---------|-------------|-----|-----|----------------|
| DTC (noriva.com) | 75-80% | $45-65 | $350-500 | 1-2 months |
| Amazon | 55-65% (after fees) | $25-40 | $200-300 | 1-2 months |
| Telehealth partnerships | 40-50% (wholesale) | $5-15 | $150-250 | <1 month |
| Healthcare provider | 45-55% | $10-20 | $250-400 | <1 month |
| Retail | 35-45% | N/A (trade spend) | Lower (less subscription) | 2-4 months |

---

## 8. Key Market Insights & Strategic Implications

### 8.1 The Window is NOW

1. **AG1 is already targeting GLP-1 users** — their homepage explicitly mentions "Are on GLP-1s and want additional nutritional support." But AG1 is a generic greens powder, not a GLP-1-specific solution.

2. **PubMed research is exploding** — from 1 study in 2023 to 3+ in 2025 on GLP-1 nutrient deficiency. By 2027, there will be definitive clinical guidelines recommending supplementation. First movers will capture this wave.

3. **The market is fragmented** — no single brand owns "the GLP-1 supplement" position. There are generic multivitamins, generic protein powders, and some "GLP-1 support" products emerging, but no comprehensive 4-product system from a dedicated brand.

4. **The comparison to prenatal vitamins is perfect** — prenatal vitamins are a $2.5B market because they serve a specific life stage with specific nutritional needs. GLP-1 supplements serve a larger and faster-growing population with equally specific needs.

### 8.2 Strategic Positioning

**Noriva should be:**
- The "prenatal vitamin of the GLP-1 era" — the obvious, default choice
- The trusted authority on GLP-1 nutrition (content-first brand)
- A system, not a product (4 products + bundle creates ecosystem lock-in)
- Premium but accessible ($44.99/product, $129.99/bundle)

**Noriva should NOT be:**
- A GLP-1 medication provider (stay in supplements, not telehealth)
- A generic supplement brand that "also does GLP-1"
- A single-product company (system > product)
- Positioned as "treating" GLP-1 side effects (regulatory risk)

---

*Sources: KFF Health Tracking Poll May 2024, Urbina et al. Clinical Obesity 2026, Neeland et al. Diabetes Obesity & Metabolism 2024, Wilding et al. NEJM 2021 (STEP 1), Jastreboff et al. NEJM 2022 (SURMOUNT-1), Alsuwailem et al. Cureus 2025, AG1 website, Found website, Calibrate website, PubMed literature search January 2026.*
